Dialysis dependence is associated with poor prognosis in multiple myeloma: a multicenter retrospective cohort study
Authors:
Open Access
- 21 August 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Abstract
Background: Patients with multiple myeloma (MM) and renal impairment (RI), particularly those requiring dialysis, have historically experienced poor outcomes. Despite advancements in targeted therapies, the prognosis of dialysis-dependent MM and factors influencing dialysis independence remain unclear. Objectives: This study aimed to provide a comprehensive analysis of the clinical manifestations and treatment outcomes of dialysis-dependent MM patients in China, and to explore the factors associated with dialysis independence and long-term survival. Design: We conducted a multicenter, retrospective, real-world cohort study. Methods: This multicenter, retrospective study included 122 MM patients requiring chronic hemodialysis (⩾28 days of treatment) at 4 comprehensive hospitals in China from January 2012 to November 2023. Hemodialysis resulting from causes other than MM was excluded. Logistic regression was employed for multivariate analysis of factors associated with dialysis independence, and Kaplan–Meier survival curves and Cox proportional hazard models were utilized for survival analysis. Results: Among the 122 patients, 74 patients (60.7%) were male, with a median age of 65 (39–87) years. Of these, 71.3% ( n = 87) had newly diagnosed MM (NDMM), and 28.7% ( n = 35) had relapsed/refractory MM (RRMM). Dialysis independence was achieved in 27 patients (22 with NDMM and 5 with RRMM). Proteasome inhibitors were used in 80.3% of patients ( n = 98), while 13.9% ( n = 17) received daratumumab-based regimens. After a median follow-up of 43.7 months, the median progression-free survival (PFS) was 14.4 months (95% confidence interval (CI): 3.6–25.2), and the median overall survival (OS) was 27.4 months (95% CI: 6.9–47.9). Dialysis-independent patients had significantly longer PFS (36.7 vs 9.4 months, p = 0.006) and OS (62.6 vs 17.7 months, p < 0.001). Factors associated with dialysis independence included achieving a very good partial response (VGPR), receiving daratumumab-based regimens, reduction in serum-free light chain ⩾80% after the first chemotherapy cycle, and age <65 years. Conclusion: In the era of new drugs, dialysis-dependent MM still has a poor prognosis, although dialysis independence improves survival.Keywords
Funding Information
- National Natural Science Foundation of China (82000221)
- National Natural Science Foundation of China (U22A20291)
This publication has 41 references indexed in Scilit:
- Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE studyAmerican Journal of Hematology, 2023
- Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patientsJournal of Clinical Laboratory Analysis, 2020
- Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimenInternational Journal of Hematology, 2020
- Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases RegistryClinical Lymphoma Myeloma and Leukemia, 2019
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple MyelomaIndian Journal of Hematology and Blood Transfusion, 2019
- Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast NephropathyJAMA, 2017
- Priapism as the Presenting Manifestation of Multiple MyelomaIndian Journal of Hematology and Blood Transfusion, 2016
- Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysisAmerican Journal of Hematology, 2016
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014